Results 41 to 50 of about 9,215 (199)
Advanced Science, EarlyView.This work designed an injectable metal‐drug supramolecular condensate formed from hafnium ions and alendronate (Hf‐ALN) and loaded with the COX‐2 inhibitor celecoxib (CXB) for synergistic radioimmunotherapy of postoperative osteosarcoma. Mechanistically, upon X‐ray irradiation, Hf enhances radiation energy deposition, ROS generation, and DNA damage ...
Tianhua Xiao +12 more
wiley +1 more source
Radioimmunotherapy of Lymphoma
Archive of Oncology, 2012 Radiolabeled monoclonal antibodies for the treatment of follicular low-grade non-Hodgkin’s lymphoma have been available for several years in the United States and more recently throughout Europe. Since their introduction to treatment of refractory or relapsed patients, they have been evaluated for efficacy earlier in the course of the disease including
openaire +3 more sources
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
British Journal of Clinical Pharmacology, EarlyView.CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
, 2018 Molecular nuclear medicine plays an important role in the diagnosis and therapy of cancer. Radioimmunodetection and radioimmunotherapy (RIT) involve the use of antibodies conjugated with diagnostic or therapeutic radionuclides, respectively ...
Baranova, A. A. +5 more
core
Radioimmunotherapy for high-grade glioma
, 2013 Patients with high-grade glioma (HGG) still have a very poor prognosis. The infiltrative nature of the tumor and the inter- and intra-tumoral cellular and genetic heterogeneity, leading to the acquisition of new mutations over time, represent the main ...
Pompucci, Angelo +5 more
core +1 more source
BMEMat, EarlyView.Synthesis of QZCaCO3‐PEG to synergistically enhance the immunogenicity of radiotherapy through concurrent Zn2+‐induced cancer cell pyroptosis and Que‐mediated hypoxia amelioration through sequentially suppressing TGF‐β secretion and ECM deposition. Abstract Radiotherapy has demonstrated broad applications in treating solid tumors, but the hostile tumor
Chunjie Wang +9 more
wiley +1 more source
Molecular theranostics: principles, challenges and controversies
Journal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley +1 more source
CD38‐Targeted Theranostics of Lymphoma with 89Zr/177Lu‐Labeled Daratumumab
Advanced Science, 2021 Lymphoma is a heterogeneous disease with varying clinical manifestations and outcomes. Many subtypes of lymphoma, such as Burkitt′s lymphoma and diffuse large B cell lymphoma, are highly aggressive with dismal prognosis even after conventional ...
Lei Kang +13 more
doaj +1 more source
Recent Advances in Hepatocellular Carcinoma Treatment with Radionuclides
Pharmaceuticals, 2022 As the third leading cause of cancer death worldwide, hepatocellular carcinoma (HCC) is characterized by late detection, difficult diagnosis and treatment, rapid progression, and poor prognosis.
Ruiqi Liu +4 more
doaj +1 more source
Precision Radiation Oncology, EarlyView.This study underscores the critical role of PTMs in mediating cellular responses to X‐ray and Carbon ion irradiation radiotherapy in HNSCC. The integration of multi‐omics data provides insights into the molecular mechanisms underlying radiation‐induced changes, offering valuable clues for improving therapeutic outcomes and advancing precision medicine ...
Fan‐Tong Xia +13 more
wiley +1 more source